Tuesday May 22 | BioSpace
Vical Incorporated Announces Publication of Herpes Simplex Vaccine Mouse Study Data
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia SAN DIEGO, May 22, 2012 -- Vical Incorporated today announced the online publication of a new article1 in The Journal of General Virology detailing results from the company's ... (more)
Vical's CEO Presents at Bank of America Merrill Lynch Health Care Conference Call
Okay, thanks very much everybody for joining us for our next presentation. My name is Rachel McMinn, I'm one of the biotech analyst here at Bank of America Merrill Lynch.
Vical Incorporated Updates Herpes Simplex Vaccine Development at Conference
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia PHILADELPHIA, May 16, 2012 -- Vical Incorporated today announced that results from multiple animal studies with the company's VaxfectinA -formulated plasmid DNA vaccines ... (more)
Vical to Present at Upcoming Investor Conferences
Vical Incorporated today announced that the company will provide an overview of its technologies, development programs, and outlook at two upcoming investor conferences.
Vical Incorporated Reports First Quarter 2012 Financial Results and...
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia SAN DIEGO, May 2, 2012 -- Vical Incorporated today reported financial results for the quarter ended March 31, 2012.
Vical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
I would now like to turn the conference over to Mr. Alan Engbring, Executive Director of Investor Relations.
Vical: An Update On My $3 Biotech Lottery Ticket
I penned an article in mid-February on a small biotech company called Vical . At the time I thought it was a great high risk/high reward play for aggressive investors in the biotech space.